Eligibility & vaccine selection — Australian Immunisation Handbook 2025
💡 4-dose oral course may provide better protection than 3 doses (ATAGI recommendation).
Revaccination is recommended for those with ongoing or long-term exposure to Salmonella Typhi (long-term travel, living in endemic region, occupational).
Parenteral (Typhim Vi):⚠️ No prospective clinical trials in travellers — benefit is supported by epidemiological evidence. Vaccine effectiveness estimated at ~65% over 3 years in travellers.
| Feature | Typhim Vi (parenteral) | Vivotif Oral |
|---|---|---|
| Type | Vi polysaccharide — inactivated | Live attenuated (Ty21a) |
| Route | IM injection, 0.5 mL | Oral capsule |
| Min. age | ≥2 years | ≥6 years |
| Doses | 1 dose | 3 (days 1,3,5) or 4 (add day 7) |
| Taken with food? | N/A | 1 hour BEFORE food, swallow whole |
| Revaccination | Every 3 years (ongoing exposure) | 3 yr after 3-dose; 5 yr after 4-dose |
| Pregnancy | Precaution — avoid unless essential | Contraindicated (ATAGI) |
| Immunocompromised | ✅ Preferred option | 🚫 Contraindicated |
| Antibiotics | ✅ No interaction | 🚫 Defer — antibiotics inactivate vaccine |
| Sponsor | Sanofi-Aventis Australia | Biocelect Pty Ltd |
| NIP funded? | ❌ Not funded — private prescription | |
Source: Australian Immunisation Handbook (last reviewed 2 May 2025). For current product information visit the TGA website.